BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Simsek C, Selek S, Koca M, Haznedaroglu IC. Proteomic and transcriptomic analyses to explain the pleiotropic effects of Ankaferd blood stopper. SAGE Open Med 2017;5:2050312117722569. [PMID: 28839937 DOI: 10.1177/2050312117722569] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Samakar B, Mehri S, Hosseinzadeh H. A review of the effects of Urtica dioica (nettle) in metabolic syndrome. Iran J Basic Med Sci 2022;25:543-53. [PMID: 35911652 DOI: 10.22038/IJBMS.2022.58892.13079] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Sarı H, Çelik S, Çağlar F, Aktaş S, Bozkurt O, Yörükoğlu K, Çelebi İ, Mungan MU. A candidate antineoplastic herbal agent for bladder cancer: Ankaferd Blood Stopper. Int J Clin Pract 2021;75:e14789. [PMID: 34480836 DOI: 10.1111/ijcp.14789] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Zeki ÖC, Nenni M, Çelebier M, Öncül S, Ercan A, Süslü İ, Haznedaroğlu İC. Antitumor activity of Ankaferd Blood Stopper® on MCF-7 breast cancer: A proteomic approach to ascertain the mechanism of the action. Journal of Herbal Medicine 2021;28:100449. [DOI: 10.1016/j.hermed.2021.100449] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Ergin M, Özer N. Comparison of hemostatic efficacy of topical Ankaferd Blood Stopper on heparinized and nonheparinized rats in bleeding related to liver injury. Acta Cir Bras 2021;36:e360106. [PMID: 33533829 DOI: 10.1590/ACB360106] [Reference Citation Analysis]
5 Kocaman N, Altun S, Bal A, Ozcan EC, Sarac M, Artas G, Demir B, Aydin S, Kuloglu T. Effects of Carnosine, Ankaferd, and Silver Sulfadiazine on an Experimental Burn Model: Roles of Irisin and HSP70. J Burn Care Res 2021;42:408-14. [PMID: 32910166 DOI: 10.1093/jbcr/iraa156] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Beyazit F, Beyazit Y, Tanoglu A, Haznedaroglu IC. Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content. Med Hypotheses 2020;143:110150. [PMID: 32763660 DOI: 10.1016/j.mehy.2020.110150] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Koçak E, Çelebier M, Haznedaroglu IC, Altınöz S. Analysis of the Antiproliferative Effect of Ankaferd Hemostat on Caco-2 Colon Cancer Cells via LC/MS Shotgun Proteomics Approach. Biomed Res Int 2019;2019:5268031. [PMID: 31240215 DOI: 10.1155/2019/5268031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
8 Büyük B, Beyazıt F. The efficacy of Ankaferd Blood Stopper® in an experimental Asherman syndrome model created in rats. Turk J Obstet Gynecol 2019;16:7-14. [PMID: 31019834 DOI: 10.4274/tjod.galenos.2018.21298] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
9 Beyazit F, Buyuk B. An immunohistochemistry and histopathological study of ankaferd blood stopper in a rat model of cervical inflammation. Rev Assoc Med Bras (1992) 2019;65:183-90. [PMID: 30892442 DOI: 10.1590/1806-9282.65.2.183] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]